SAB Biotherapeutics, Inc. SABS
Biotechnology: Biological Products (No Diagnostic Substances) · IPO 2021 · data as of November 13, 2026
SAB Biotherapeutics, Inc. (SABS) is a healthcare company listed in the US with a market value of about $267M.
Its overall Stock Analiz score is 0.4 out of 5 (weak). The strongest part is financial health (2/5); the weakest is value (0/5).
Key numbers: a 5-year average ROIC of -64%.
About SAB Biotherapeutics
SAB Biotherapeutics is listed in the US and classified in biotechnology: biological products (no diagnostic substances), IPO year 2021. Revenue went from $55M in 2020 to $1M in 2024, a decline of about 60.7% a year. It was profitable in 2 of the last 6 years in our data. Its share count rose by 1309% over three years (dilution for shareholders).
Score: 0.4 / 5
Checks passed
- More cash than debt, or low debt to equity
- Liabilities below 60% of assets
Checks not passed
- P/E below 25
- P/E below the industry median
- P/FCF below 20
- Price below intrinsic value (DCF, moderate assumptions)
- PEG below 1.5
- Revenue growth above 10% last year
- 3-year revenue growth above 10% a year
- Profit margin improving
Valuation
Growth and quality
Financials, last 6 years
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|
| Revenue | — | $1M | $2M | $24M | $61M | $55M |
| Net income | $13M | -$34M | -$42M | -$19M | -$17M | $20M |
| Free cash flow | -$46M | -$35M | -$25M | -$26M | -$9M | -$3M |
| EPS (diluted) | $-0.79 | $-3.68 | $-7.64 | $-4.31 | $-6.30 | $7.40 |
| Net margin | — | -2579.0% | -1884.5% | -78.4% | -28.2% | 36.4% |
| ROIC | -31.8% | -124.5% | -63.8% | -68.8% | -31.0% | 47.8% |
From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.
What analysts expect
The average 12-month price target from 11 analysts is $11.64, 293% above the current price; targets range from $6.00 to $16.00; the consensus rating is “Strong buy”; expected EPS is $-1.13 for the fiscal year ending December 31, 2026.
Frequently asked questions
Does SAB Biotherapeutics pay a dividend?
Not currently.
Is SAB Biotherapeutics a good stock to buy?
We do not give buy or sell advice. SAB Biotherapeutics scores 0.4 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.
Similar companies
Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.